Current dosage and schedule issues in the development of paclitaxel (Taxol).
Basic questions regarding optimal dose and schedule of anticancer drug administration frequently persist long after regulatory approval and commercial availability of a drug. For paclitaxel (TAXOL), these questions were considered early in drug development. This paper reviews the available preclinical studies that assessed different drug concentrations and durations of drug exposure. The current status of clinical trials designed to help resolve these issues is also reviewed.
Arbuck
S G
SG
Developmental Chemotherapy Section, National Cancer Institute, Bethesda, MD 20892.
Canetta
R
R
Onetto
N
N
Christian
M C
MC
D000818:Animals; D001855:Bone Marrow Diseases / Q000139:chemically induced; D002986:Clinical Trials as Topic; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D004342:Drug Hypersensitivity / Q000209:etiology; D006801:Humans; D051379:Mice; D008870:Microtubules / Q000187:drug effects; D009369:Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D051381:Rats; D013997:Time Factors
D017239:Paclitaxel